DK2481402T3 - Nanopartikel, der omfatter rapamycin og albumin som middel mod cancer - Google Patents

Nanopartikel, der omfatter rapamycin og albumin som middel mod cancer Download PDF

Info

Publication number
DK2481402T3
DK2481402T3 DK12152455.7T DK12152455T DK2481402T3 DK 2481402 T3 DK2481402 T3 DK 2481402T3 DK 12152455 T DK12152455 T DK 12152455T DK 2481402 T3 DK2481402 T3 DK 2481402T3
Authority
DK
Denmark
Prior art keywords
cancer
rapamycin
composition
derivative
examples
Prior art date
Application number
DK12152455.7T
Other languages
English (en)
Inventor
Vuong Trieu
Neil P Desai
Patrick Soon-Shiong
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Application granted granted Critical
Publication of DK2481402T3 publication Critical patent/DK2481402T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (14)

1. Sammensætning, der omfatter nanopartikler, som omfatter rapamycin eller et derivat deraf og et bærerprotein, til anvendelse i en fremgangsmåde til I behandling af cancer hos et individ, hvor fremgangsmåden endvidere omfatter en anden terapi, hvor den anden terapi omfatter administration af erlotinib, perifosin eller doxorubicin, og hvor derivatet er valgt fra gruppen bestående af benzoyl-rapamycin, oxaazacyclohentriacontin, temsirolimus (CCI 779 (Wyeth)), everolimus (RAD 001 (Novartis)), pimecrolimus (ASM981), 32-deoxo-rapamycin i (SAR943), zotarolimus (ABT-578), ridaforolimus (AP23573) og Biolimus A9.
2. Sammensætning til anvendelse ifølge krav 1, hvor mængden af rapamycin eller derivatet deraf i sammensætningen er i området fra 54 mg til 540 mg.
3. Sammensætning til anvendelse ifølge krav 2, hvor mængden af rapamycin eller derivatet deraf i sammensætningen er i området fra 54 mg til 175 mg.
4. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor den anden terapi omfatter administration af erlotinib. i
5. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor canceren er valgt fra gruppen bestående af blærecancer, multipelt myelom, hjernecancer, pankreascancer, plasmacytom, nyrecellekarcinom, prostatacancer, lungecancer, melanom, brystcancer, mesoteliom, neuroendokrin cancer, i ovariecancer, lymfom, lymfoid neoplasme, myelom, leukæmi, skjoldbruskkirtelcancer, sarkom, HER2-positiv brystcancer, HER2-negativ brystcancer, kronisk myelogen leukæmi, endometriecancer og pladecellekarcinom i hoved og hals.
6. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor sammensætningen skal administreres ad en intravenøs, intraarteriel, intraperitoneal, intravesikulær, subkutan, intratekal, intrapulmonær, intramuskulær, intratrakeal, intraokulær, transdermal eller oral vej eller via inhalation.
7. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 6, i hvor bærerproteinet er albumin.
8. Sammensætning til anvendelse ifølge krav 7, hvor albuminet er humant serumalbumin.
9. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 8, hvor den gennemsnitlige diameter for nanopartiklerne, der omfatter rapamycin eller derivatet deraf, ikke er større end ca. 200 nm, fortrinsvis ikke større end ca. 100 nm.
10. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 9, hvor nanopartiklerne, der omfatter rapamycin eller derivatet deraf, er overtrukket med bærerproteinet.
11. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 10, i hvor sammensætningen omfatter nanopartikler, der omfatter rapamycin.
12. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 11, hvor canceren er brystcancer.
13. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 12, hvor fremgangsmåden omfatter administration af sammensætningen ad en intravenøs vej.
14. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 13, i hvor individet er et menneske.
DK12152455.7T 2007-03-07 2008-03-07 Nanopartikel, der omfatter rapamycin og albumin som middel mod cancer DK2481402T3 (da)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US90576707P 2007-03-07 2007-03-07
US90566907P 2007-03-07 2007-03-07
US90566307P 2007-03-07 2007-03-07
US90573407P 2007-03-07 2007-03-07
US90566207P 2007-03-07 2007-03-07
US90573507P 2007-03-07 2007-03-07
US90575007P 2007-03-07 2007-03-07
US90578707P 2007-03-07 2007-03-07
US90567207P 2007-03-07 2007-03-07
US92345607P 2007-04-13 2007-04-13
US92324807P 2007-04-13 2007-04-13
EP08726605.2A EP2131821B1 (en) 2007-03-07 2008-03-07 Nanoparticle comprising rapamycin and albumin as anticancer agent

Publications (1)

Publication Number Publication Date
DK2481402T3 true DK2481402T3 (da) 2018-08-06

Family

ID=39562000

Family Applications (3)

Application Number Title Priority Date Filing Date
DK12152463.1T DK2481409T3 (da) 2007-03-07 2008-03-07 Nanopartikel, der omfatter rapamycin og albumin som middel mod cancer
DK08726605.2T DK2131821T3 (da) 2007-03-07 2008-03-07 Nanopartikel, der omfatter rapamycin og albumin som middel mod cancer
DK12152455.7T DK2481402T3 (da) 2007-03-07 2008-03-07 Nanopartikel, der omfatter rapamycin og albumin som middel mod cancer

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK12152463.1T DK2481409T3 (da) 2007-03-07 2008-03-07 Nanopartikel, der omfatter rapamycin og albumin som middel mod cancer
DK08726605.2T DK2131821T3 (da) 2007-03-07 2008-03-07 Nanopartikel, der omfatter rapamycin og albumin som middel mod cancer

Country Status (24)

Country Link
US (6) US8911786B2 (da)
EP (4) EP2481409B1 (da)
JP (6) JP2010520289A (da)
KR (5) KR102047634B1 (da)
CN (1) CN104814930B (da)
AU (1) AU2008223334B2 (da)
BR (1) BRPI0808635B1 (da)
CA (3) CA3006137C (da)
CY (3) CY1120555T1 (da)
DK (3) DK2481409T3 (da)
ES (3) ES2690174T3 (da)
HR (3) HRP20181159T1 (da)
HU (3) HUE039643T2 (da)
IL (2) IL200755A (da)
LT (3) LT2131821T (da)
MX (1) MX2009009537A (da)
NZ (2) NZ711695A (da)
PL (3) PL2481402T3 (da)
PT (3) PT2481409T (da)
RU (3) RU2483714C2 (da)
SI (3) SI2131821T1 (da)
UA (1) UA118645C2 (da)
WO (1) WO2008109163A1 (da)
ZA (1) ZA200906342B (da)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
CN104587479A (zh) 2002-12-09 2015-05-06 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
PT1853250E (pt) 2005-02-18 2012-02-03 Abraxis Bioscience Llc Combinações e modos de administração de agentes terapêuticos e terapia de combinação
CN103054798B (zh) 2005-08-31 2021-03-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
AU2007334360B2 (en) 2006-12-14 2013-10-17 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
HUE039643T2 (hu) * 2007-03-07 2019-01-28 Abraxis Bioscience Llc Rapamicin rákellenes szert és albumint tartalmazó nanorészecske
CA2686736A1 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension
EP2155188B1 (en) * 2007-06-01 2013-10-09 Abraxis BioScience, LLC Methods and compositions for treating recurrent cancer
US20100048914A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2009126401A1 (en) * 2008-04-10 2009-10-15 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
WO2010005725A2 (en) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
ES2765240T3 (es) 2008-06-16 2020-06-08 Pfizer Nanopartículas poliméricas cargadas de fármaco y procedimientos de fabricación y uso de las mismas
MX2011005667A (es) * 2008-11-28 2011-06-16 Novartis Ag Combinacion farmaceutica que comprende un inhibidor de hsp90 y un inhibidor de mtor.
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
EP3023433A1 (en) 2009-02-05 2016-05-25 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
KR20120061081A (ko) * 2009-04-10 2012-06-12 하이얀 치 새로운 노화 방지 물질 및 그 확인 방법
WO2010121000A1 (en) 2009-04-15 2010-10-21 Abraxis Bioscience, Llc Prion-free nanoparticle compositions and methods
EP2509634B1 (en) 2009-12-11 2019-03-06 Pfizer Inc Stable formulations for lyophilizing therapeutic particles
JP5965844B2 (ja) 2009-12-15 2016-08-10 バインド セラピューティックス インコーポレイテッド 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物
KR101267813B1 (ko) * 2009-12-30 2013-06-04 주식회사 삼양바이오팜 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
GB2478556A (en) * 2010-03-09 2011-09-14 Myrovlytis Technology Ventures Ltd A composition for use in the treatment of Birt-Hogg-Dubô sydrome
PL2552438T3 (pl) 2010-03-26 2016-12-30 Sposoby leczenia raka wątrobowokomórkowego
MX364637B (es) 2010-03-29 2019-05-03 Abraxis Bioscience Llc Star Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc.
CA2794147A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
WO2011133668A2 (en) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer
KR20190130050A (ko) 2010-06-04 2019-11-20 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
WO2012054564A2 (en) * 2010-10-19 2012-04-26 The Curators Of The University Of Missouri Anti-vegf antibody/fragment conjugated gold nanoparticles, and fabrication and therapeutic methods
US8691777B2 (en) 2011-01-27 2014-04-08 Emory University Combination therapy
KR20200051841A (ko) * 2011-04-28 2020-05-13 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물의 혈관내 전달 및 그의 용도
MX2013012593A (es) 2011-04-29 2014-08-21 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
US9427477B2 (en) 2011-05-09 2016-08-30 Mayo Foundation For Medical Education And Research Cancer treatments
CN109771377A (zh) 2011-12-14 2019-05-21 阿布拉科斯生物科学有限公司 用于颗粒冻干或冷冻的聚合物赋形剂
WO2013148158A1 (en) * 2012-03-30 2013-10-03 President And Fellows Of Harvard College Laser-actuated therapeutic nanoparticles
CN104582732A (zh) 2012-06-15 2015-04-29 布里格姆及妇女医院股份有限公司 治疗癌症的组合物及其制造方法
US9119858B2 (en) * 2012-08-21 2015-09-01 Genesys Research Institute, Inc. Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
KR20150056619A (ko) * 2012-09-17 2015-05-26 바인드 쎄라퓨틱스, 인크. 치료제를 포함하는 치료 나노입자 및 그의 제조 및 사용 방법
EP2895156B1 (en) 2012-09-17 2019-05-08 Pfizer Inc. Process for preparing therapeutic nanoparticles
WO2014055415A1 (en) 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9918968B2 (en) * 2013-01-03 2018-03-20 The Board Of Regents Of The University Of Texas System Rapamycin analogs targeting proteasome function in the treatment of cancer
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
ES2797376T3 (es) 2013-01-24 2020-12-02 Palvella Therapeutics Inc Composiciones para la administración transdérmica de inhibidores de mTOR
KR102191311B1 (ko) 2013-03-12 2020-12-15 아브락시스 바이오사이언스, 엘엘씨 폐암의 치료 방법
EP2968370A4 (en) 2013-03-14 2016-09-21 Univ Maryland AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF
CA2903548A1 (en) * 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
WO2014144405A1 (en) * 2013-03-15 2014-09-18 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of neuroendocrine tumor development and growth
KR101329646B1 (ko) 2013-05-02 2013-11-14 주식회사 지니스 표적지향증폭형 항암나노입자 및 이의 제조방법
CA2910579C (en) * 2013-05-03 2023-09-26 Selecta Biosciences, Inc. Dosing combinations for reducing undesired humoral immune responses
KR20220025907A (ko) * 2013-05-03 2022-03-03 셀렉타 바이오사이언시즈, 인크. 비-알레르겐성 항원에 반응하는 아나필락시스를 감소시키거나 방지하기 위한 관용유발 합성 나노담체
BR112016002970A2 (pt) 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
AP2016009088A0 (en) 2013-09-16 2016-03-31 Astrazeneca Ab Therapeutic polymeric nanoparticles and methods of making and using same
CN106061470A (zh) * 2013-10-22 2016-10-26 北卡罗来纳大学查珀尔希尔分校 含有多种物质的聚合物纳米粒子及其方法
EP3089737B1 (en) 2013-12-31 2021-11-03 Rapamycin Holdings, LLC Oral rapamycin nanoparticle preparations and use
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
TWI693937B (zh) 2014-03-14 2020-05-21 美商輝瑞大藥廠 包含治療劑之治療性奈米顆粒及其製造及使用方法
US10213513B2 (en) 2014-06-16 2019-02-26 Mayo Foundation For Medical Education And Research Treating myelomas
MX2017002931A (es) 2014-09-07 2017-05-30 Selecta Biosciences Inc Metodos y composiciones para atenuar respuestas inmunes anti-vector de transferencia viral.
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
WO2016172069A1 (en) * 2015-04-20 2016-10-27 Washington State University Methods of treating inflammation associated airway diseases and viral infections
US20160346219A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
MX2017016519A (es) * 2015-06-29 2018-08-16 Abraxis Bioscience Llc Biomarcadores para composiciones de nanoparticulas.
NZ738929A (en) * 2015-06-29 2024-01-26 Abraxis Bioscience Llc Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
KR102606071B1 (ko) * 2015-06-29 2023-11-27 아브락시스 바이오사이언스, 엘엘씨 상피양 세포 종양을 치료하는 방법
MX2017016491A (es) * 2015-06-29 2018-08-16 Abraxis Bioscience Llc Metodos para tratar malignidad hematologica usando terapia combinada de nanoparticulas de inhibidor de objetivo mamifero de la rapamicina (mtor).
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
AU2016308337B2 (en) * 2015-08-18 2019-02-28 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
ES2837484T3 (es) 2016-02-04 2021-06-30 Univ Johns Hopkins Rapadocinas, inhibidores del transportador de nucleósidos equilibrativo 1 y usos de los mismos
CN108697729B (zh) * 2016-02-04 2023-05-09 约翰霍普金斯大学 新型GLUT抑制剂rapaglutin及其用途
AU2017217881B2 (en) 2016-02-12 2022-11-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
US11585805B2 (en) 2016-02-19 2023-02-21 Nantcell, Inc. Methods of immunogenic modulation
WO2017156191A1 (en) * 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
WO2017165440A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US11878061B2 (en) 2016-03-21 2024-01-23 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
JP2019526579A (ja) 2016-09-01 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｔ細胞癌を標的とする為の方法及び組成物
EP3506942B1 (en) 2016-09-01 2022-11-16 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
CN109890422A (zh) 2016-09-06 2019-06-14 梅约医学教育与研究基金会 紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法
WO2018048815A1 (en) 2016-09-06 2018-03-15 Nantibodyfc, Llc Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
EP3510048A1 (en) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Methods of treating pd-l1 expressing cancer
CA3038824A1 (en) * 2016-09-28 2018-04-05 Abraxis Bioscience, Llc Methods of treating mitochondrial and metabolic disorders
ES2944576T3 (es) * 2017-01-06 2023-06-22 Santen Pharmaceutical Co Ltd Administración intratumoral de sirólimus para el tratamiento del cáncer de próstata
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
KR20190124295A (ko) 2017-03-11 2019-11-04 셀렉타 바이오사이언시즈, 인크. 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물
US10806801B2 (en) * 2017-06-07 2020-10-20 National Cheng Kung University Pharmaceutical composition and methods for using the same
WO2019073371A1 (en) 2017-10-11 2019-04-18 Wockhardt Limited PHARMACEUTICAL COMPOSITION COMPRISING ALBUMIN-LIPID HYBRID NANOPARTICLES
CN111683657A (zh) * 2017-12-19 2020-09-18 阿布拉科斯生物科学有限公司 利用纳米颗粒mTOR抑制剂联合疗法治疗结肠癌的方法
US20200316037A1 (en) * 2017-12-21 2020-10-08 The Angiogenesis Foundation Compositions and methods for treating neoplasia
CN111712231A (zh) * 2018-02-23 2020-09-25 百多力股份公司 用于40-o-环状烃酯和相关结构的肠胃外制剂材料和方法
RU2020134124A (ru) * 2018-03-20 2022-04-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ
CA3100905A1 (en) 2018-05-22 2019-11-28 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
EP3941551A4 (en) * 2019-03-19 2023-01-18 Abraxis BioScience, LLC SUBCUTANEOUS ADMINISTRATION OF NANOPARTICLES COMPRISING MTOR INHIBITOR AND ALBUMIN FOR THE TREATMENT OF DISEASES
US20220257523A1 (en) * 2019-07-16 2022-08-18 The Regents Of The University Of Michigan Composite drug particles and uses thereof
AU2020375810A1 (en) * 2019-10-28 2022-05-12 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
EP4058000A4 (en) * 2019-11-11 2024-02-28 Abraxis BioScience, LLC BIOMARKERS FOR NANOPARTICLE COMPOSITIONS
KR102641217B1 (ko) * 2019-12-24 2024-02-29 (주)아이엠지티 항암제가 코팅된 알부민 나노입자 및 이의 제조방법
KR102517033B1 (ko) 2020-07-15 2023-04-03 성균관대학교산학협력단 엔도텔린 수용체 길항제를 봉입한 나노입자 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
EP4259207A1 (en) * 2020-12-10 2023-10-18 Children's Hospital Medical Center Enhanced nanoparticle delivery systems
EP4326260A1 (en) * 2021-04-20 2024-02-28 The Regents of The University of Michigan Pi3k inhibitors, nanoformulations, and uses thereof
KR20240044603A (ko) 2022-09-28 2024-04-05 충남대학교산학협력단 피로인산티아민 알부민 나노클러스터를 포함하는 항암치료용 조성물 및 이의 제조방법
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5997904A (en) 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US20030068362A1 (en) 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US20070117863A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US6528067B1 (en) * 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
DK0693924T4 (da) 1993-02-22 2008-08-04 Abraxis Bioscience Inc Fremgangsmåde til (in vivo) levering af biologiske materialer og sammensætninger, der er egnede dertil
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
EP1683517A1 (en) 1996-08-19 2006-07-26 American Bioscience, Inc. Methods for the production of protein particles useful for delivery of pharmacological agents
US8137684B2 (en) * 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
CN100462066C (zh) * 1997-06-27 2009-02-18 美国生物科学有限公司 药剂的新制剂及其制备和应用方法
WO2000064437A1 (en) 1999-04-22 2000-11-02 American Biosciences, Inc. Long term administration of pharmacologically active agents
EP1178786A4 (en) 1999-05-21 2006-03-01 American Bioscience Inc PHARMACOLOGICALLY ACTIVE PROTEIN STABILIZING AGENTS; METHODS OF MANUFACTURE AND METHODS OF USE
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
ITMI20001107A1 (it) 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
EP2269603B1 (en) * 2001-02-19 2015-05-20 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with exemestane
IL157898A0 (en) 2001-04-06 2004-03-28 Wyeth Corp Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
SG153647A1 (en) * 2001-06-01 2009-07-29 Wyeth Corp Antineoplastic combinations
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
JP4212921B2 (ja) * 2002-03-29 2009-01-21 独立行政法人科学技術振興機構 抗体を提示するタンパク質中空ナノ粒子を用いる治療薬剤およびタンパク質中空ナノ粒子
WO2003086178A2 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
US20040126400A1 (en) * 2002-05-03 2004-07-01 Iversen Patrick L. Delivery of therapeutic compounds via microparticles or microbubbles
CN104587479A (zh) * 2002-12-09 2015-05-06 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
KR20190034694A (ko) 2002-12-09 2019-04-02 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
WO2004060283A2 (en) * 2002-12-16 2004-07-22 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US20050038498A1 (en) * 2003-04-17 2005-02-17 Nanosys, Inc. Medical device applications of nanostructured surfaces
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
EP1755653B1 (en) * 2004-05-14 2014-12-31 Abraxis BioScience, LLC Treatment methods utilizing albumin-binding proteins as targets
RU2006144809A (ru) 2004-05-17 2008-06-27 Новартис АГ (CH) Комбинация органических соединений
MX366832B (es) * 2004-10-01 2019-07-24 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
WO2006053754A1 (en) 2004-11-19 2006-05-26 Novartis Ag COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
US7862588B2 (en) * 2005-02-18 2011-01-04 Samy Abdou Devices and methods for dynamic fixation of skeletal structure
PT1853250E (pt) * 2005-02-18 2012-02-03 Abraxis Bioscience Llc Combinações e modos de administração de agentes terapêuticos e terapia de combinação
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
ES2663495T3 (es) 2005-02-18 2018-04-13 Abraxis Bioscience, Llc Fármacos con hidrofobicidad mejorada para incorporación en dispositivos médicos
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
EP1868576A2 (en) * 2005-03-17 2007-12-26 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
DE102005016873A1 (de) * 2005-04-12 2006-10-19 Magforce Nanotechnologies Ag Nanopartikel-Wirstoff-Konjugate
US7514549B2 (en) * 2005-04-16 2009-04-07 Michigan State University Tumor inhibition by modulating sprouty expression or activity
AU2006247473A1 (en) 2005-05-16 2006-11-23 Novartis Ag The use of rapamycin derivatives for the treatment and/or prevention of cardiovascular disorders
CN103054798B (zh) * 2005-08-31 2021-03-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
NZ592132A (en) * 2005-08-31 2012-12-21 Abraxis Bioscience Llc Composition comprising nanoparticles of docitaxel and a citrate
US20070148251A1 (en) * 2005-12-22 2007-06-28 Hossainy Syed F A Nanoparticle releasing medical devices
CA2662140A1 (en) 2006-08-31 2008-03-06 Abraxis Bioscience, Llc Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20080280987A1 (en) 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20100112077A1 (en) * 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
AU2007334360B2 (en) * 2006-12-14 2013-10-17 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
HUE039643T2 (hu) * 2007-03-07 2019-01-28 Abraxis Bioscience Llc Rapamicin rákellenes szert és albumint tartalmazó nanorészecske
CA2686736A1 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension
EP2155188B1 (en) 2007-06-01 2013-10-09 Abraxis BioScience, LLC Methods and compositions for treating recurrent cancer
WO2009126401A1 (en) * 2008-04-10 2009-10-15 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
EP2367425B1 (en) * 2008-12-11 2018-02-28 Abraxis BioScience, LLC Combination therapy including a taxane and a further therapeutic agent
US20120189701A1 (en) * 2009-03-13 2012-07-26 Desai Neil P Combination therapy with thiocolchicine derivatives
EP2416650B1 (en) * 2009-04-10 2020-02-26 Abraxis BioScience, LLC Nanoparticle formulations and uses therof
WO2010121000A1 (en) 2009-04-15 2010-10-21 Abraxis Bioscience, Llc Prion-free nanoparticle compositions and methods
SG178873A1 (en) * 2009-08-25 2012-04-27 Abraxis Bioscience Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
US9775819B2 (en) * 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
PL2552438T3 (pl) * 2010-03-26 2016-12-30 Sposoby leczenia raka wątrobowokomórkowego
MX364637B (es) * 2010-03-29 2019-05-03 Abraxis Bioscience Llc Star Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc.
CA2794147A1 (en) * 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
NZ604029A (en) * 2010-06-02 2015-07-31 Abraxis Bioscience Llc Methods of treating bladder cancer
KR20190130050A (ko) * 2010-06-04 2019-11-20 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
US9149455B2 (en) * 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
CA2903548A1 (en) * 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer

Also Published As

Publication number Publication date
EP2481402A2 (en) 2012-08-01
EP2481409A2 (en) 2012-08-01
ES2690175T3 (es) 2018-11-19
HUE039643T2 (hu) 2019-01-28
IL200755A (en) 2017-12-31
JP2014015487A (ja) 2014-01-30
MX2009009537A (es) 2009-09-16
KR20190009842A (ko) 2019-01-29
PT2131821T (pt) 2018-10-10
SI2481402T1 (sl) 2018-09-28
PL2481402T3 (pl) 2018-11-30
US20210322335A1 (en) 2021-10-21
HRP20181217T1 (hr) 2018-10-05
CY1120548T1 (el) 2019-07-10
PL2481409T3 (pl) 2018-11-30
EP2131821A1 (en) 2009-12-16
CN104814930A (zh) 2015-08-05
EP3417859A1 (en) 2018-12-26
KR102047634B1 (ko) 2019-11-21
BRPI0808635B1 (pt) 2022-06-07
JP2020002177A (ja) 2020-01-09
LT2481409T (lt) 2018-10-25
LT2131821T (lt) 2018-09-25
BRPI0808635A2 (pt) 2014-08-05
JP6348698B2 (ja) 2018-06-27
EP2481402B1 (en) 2018-05-09
CN104814930B (zh) 2019-12-17
CA3006137C (en) 2023-08-01
CA2680207A1 (en) 2008-09-12
RU2013109422A (ru) 2014-09-10
US20240065984A1 (en) 2024-02-29
JP2016011309A (ja) 2016-01-21
UA118645C2 (uk) 2019-02-25
RU2019101632A (ru) 2020-07-22
CA3006137A1 (en) 2008-09-12
HUE038701T2 (hu) 2018-11-28
IL250445A0 (en) 2017-03-30
EP2481402A3 (en) 2012-10-17
SI2131821T1 (sl) 2018-11-30
KR20090118999A (ko) 2009-11-18
EP2131821B1 (en) 2018-05-09
KR101943230B1 (ko) 2019-01-28
US20130280336A1 (en) 2013-10-24
EP2481409A3 (en) 2012-10-10
CY1120555T1 (el) 2019-07-10
PT2481409T (pt) 2018-10-18
US8911786B2 (en) 2014-12-16
HRP20181159T1 (hr) 2018-11-02
ES2690174T3 (es) 2018-11-19
CA2680207C (en) 2018-07-03
NZ621972A (en) 2015-09-25
PT2481402T (pt) 2018-10-18
ES2686150T3 (es) 2018-10-16
DK2481409T3 (da) 2018-08-06
EP2481409B1 (en) 2018-05-09
ZA200906342B (en) 2010-11-24
US20190022020A1 (en) 2019-01-24
HRP20181198T1 (hr) 2018-10-05
RU2678448C2 (ru) 2019-01-29
IL200755A0 (en) 2010-05-17
JP2010520289A (ja) 2010-06-10
CA3201293A1 (en) 2008-09-12
KR20190130680A (ko) 2019-11-22
PL2131821T3 (pl) 2018-11-30
KR102154459B1 (ko) 2020-09-09
CY1120547T1 (el) 2019-07-10
US20100183728A1 (en) 2010-07-22
HUE039497T2 (hu) 2019-01-28
KR20170014007A (ko) 2017-02-07
RU2009136992A (ru) 2011-04-20
JP2018150381A (ja) 2018-09-27
US20150050356A1 (en) 2015-02-19
NZ711695A (en) 2017-05-26
JP2017132810A (ja) 2017-08-03
LT2481402T (lt) 2018-10-25
KR20150002886A (ko) 2015-01-07
WO2008109163A1 (en) 2008-09-12
DK2131821T3 (da) 2018-08-06
AU2008223334A1 (en) 2008-09-12
AU2008223334B2 (en) 2014-05-08
SI2481409T1 (sl) 2018-09-28
RU2483714C2 (ru) 2013-06-10
JP6544812B2 (ja) 2019-07-17

Similar Documents

Publication Publication Date Title
US20240065984A1 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
AU2013204187B2 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
AU2015271950B2 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent